Comparison · NCT00489970-d17cdac6
Boostrix Group vs Adacel Group: Number of Subjects With Anti-tetanus (Anti-T) Antibody Concentrations ≥ Protocol Specified Cut-off
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Boostrix Group vs Adacel Group: Number of Subjects With Anti-tetanus (Anti-T) Antibody Concentrations ≥ Protocol Specified Cut-off. Trial comparisons, record NCT00489970-d17cdac6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00489970-d17cdac6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.986 | 0.977 | 0.992 | wilson | |
| Risk in group 2 | 0.996 | 0.986 | 0.999 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00985 | -0.0195 | 0.00189 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.99 | 0.981 | 0.999 | log | |
| Odds ratio, group 1 over group 2 | 0.283 | 0.0642 | 1.25 | log | |
| Number needed to treat, for one fewer participant with the outcome on Boostrix Group than on Adacel Group | 101 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Boostrix Group | Subjects received in the primary study (NCT00346073) a single dose of Boostrix vaccine \[Tdap\](GSK776423) intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a second dose of Boostrix vaccine \[Tdap\](GSK776423). | 1,000 | 1,014 | OG000 |
| Group 2 | Adacel Group | Subjects received in the primary study (NCT00346073) a single dose of Adacel vaccine intramuscularly in the deltoid region of the non-dominant upper arm and in this study at Year 9 received a dose of Boostrix vaccine \[Tdap\](GSK776423). | 504 | 506 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Subjects With Anti-tetanus (Anti-T) Antibody Concentrations ≥ Protocol Specified Cut-off
- Description
- Anti-T cut-off was defined as ≥ 0.1 IU/mL as assessed by ELISA.
- Time frame
- At year 1 after the vaccination in primary study (NCT00346073)
- Population
The analysis was performed on the Adapted ATP cohort for immunogenicity, which included all evaluable subjects who met all eligibility criteria and for whom data concerning immunogenicity endpoint measures obtained from the ATP cohort for immunogenicity corresponding to each time point were available.
Source ClinicalTrials.gov
Trial
- Title
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
- NCT number
- NCT00489970
- Phases
- PHASE3
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria
- Interventions
- Taking of blood samples, Boostrix, Adacel
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2010-08-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00489970?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00489970-d17cdac6